Navigation Links
Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
Date:6/18/2009

BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulocyte macrophage colony-stimulating factor (GM-CSF) human antibody MT203 by its collaboration partner Nycomed.

The double-blind, randomized, placebo controlled study will investigate the safety and pharmacokinetics of MT203.

GM-CSF has been shown to play a significant role in various autoimmune and inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.

Under a 2007 agreement between Micromet and Nycomed, the two companies are jointly developing MT203. Micromet has been primarily responsible for the non-clinical development of MT203, whereas Nycomed will be responsible for the clinical development and commercialization of MT203 going forward.

"The initiation of the first clinical trial represents a major milestone for MT203," comments Christian Itin, President and CEO of Micromet. "Our partner Nycomed is well positioned to pursue the clinical development of MT203 in the field of severe inflammatory and autoimmune diseases."

"We are very pleased with the progress in our collaboration with Micromet," comments Anders Ulman, Executive Vice President Research and Development of Nycomed. "We are looking forward to the results of this first trial as a key milestone in our clinical development program."

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of MT203 and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ORNL finding could help electronics industry enter new phase
2. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
3. FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
4. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
5. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
6. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
7. Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
8. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
9. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
10. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
11. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , ... February 21, 2017 , ... Support of value-based ... simplify the secure exchange of data across industry solutions, Fogo Data Centers announces the ... of community. A healthy community is one in which all systems work well, ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... of the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ ... is backed by giants including Accenture, GE Ventures, and Software AG , ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... protein espresso drinks, announced its products are now available for purchase on RonnieColemanNutrition.com, ... Drink Mix has become popular among health-conscious consumers who love coffee but are ...
(Date:2/20/2017)... ... ... Nancy Johnston Toll marks her debut in the publishing scene ... in the Road ” (published by Xlibris). Inspired from her personal experiences, this compendium ... and downs experienced by anyone going through cancer treatment and how one can be ...
(Date:2/20/2017)... ... February 20, 2017 , ... For ... Orbita, Inc., a leading provider of innovative software for connected home healthcare, today ... and optimizing care journey management for home healthcare. , Built on ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... BEACH, Va. , Feb. 21, 2017  Global ... now covers Dermacell ® for breast ... foot ulcers. Dermacell is an advanced acellular dermal matrix ... Technologies, Inc. (NASDAQ: NVDQ ) ... the four major commercial health-care payers to review the ...
(Date:2/21/2017)... , Feb. 21, 2017 Sangamo Therapeutics, ... announced today that the company will release its fourth ... market opens on Tuesday, February 28, 2017. The press ... 8:30 a.m. ET, which will be open to the ... the company will review its financial results and provide ...
(Date:2/21/2017)... -- Lexmark International, Inc., ... that connects Lexmark multifunction printers (MFPs) to EDCO Health ... scanning and indexing software solutions for medical records. ... a Lexmark MFP at the point of care to ... reach HIMSS Stage 7 through state-of-the-art technology ...
Breaking Medicine Technology: